News | February 28, 2023
Sanofi reaffirms commitment to rare diseases in India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
Subscribe To Our Newsletter & Stay Updated
